Matthew David Hellmann
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 180
- Cancer Immunotherapy and Biomarkers 151
- CAR-T cell therapy research 29
- Lung Cancer Research Studies 29
-
- Lung Cancer Treatments and Mutations 65
- Lung Cancer Diagnosis and Treatment 14
- Co-authors
- Michael Andrew Postow (11 shared papers)Robert Sidlow (1 shared paper)Adam Jacob Schoenfeld (7 shared papers)Jedd D. Wolchok (19 shared papers)Mark G. Kris (30 shared papers)Jamie E. Chaft (24 shared papers)Hira A. Rizvi (21 shared papers)Naiyer A. Rizvi (20 shared papers)
- Journals
- Annals of Oncology (41 papers)Journal of Thoracic Oncology (29 papers)Clinical Cancer Research (20 papers)Journal for ImmunoTherapy of Cancer (14 papers)Journal of Clinical Oncology (13 papers)
- Partner nations
- United StatesSpainGermany
In The Last Decade
Matthew David Hellmann
239 papers receiving 76.7k citations
Matthew David Hellmann's Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 47.2k
- Immunology 17.5k
- Cancer Research 10.9k
- Pulmonary and Respiratory Medicine 20.8k
- Pathology and Forensic Medicine 4.0k
Countries citing papers authored by Matthew David Hellmann
This map shows the geographic impact of Matthew David Hellmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew David Hellmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew David Hellmann more than expected).
Fields of papers citing papers by Matthew David Hellmann
This network shows the impact of papers produced by Matthew David Hellmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew David Hellmann. The network helps show where Matthew David Hellmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Matthew David Hellmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 244 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Hit paper breakdown → | 2015 | 6617 |
| 2 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 5263 |
| 3 | Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors Hit paper breakdown → | 2017 | 4482 |
| 4 | Immune-Related Adverse Events Associated with Immune Checkpoint Blockade Hit paper breakdown → | 2018 | 3780 |
| 5 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types Hit paper breakdown → | 2019 | 3019 |
| 6 | Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Hit paper breakdown → | 2017 | 2650 |
| 7 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Hit paper breakdown → | 2016 | 2528 |
| 8 | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Hit paper breakdown → | 2018 | 2504 |
| 9 | Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2019 | 2191 |
| 10 | OncoKB: A Precision Oncology Knowledge Base Hit paper breakdown → | 2017 | 1972 |
| 11 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 1831 |
| 12 | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer Hit paper breakdown → | 2018 | 1647 |
| 13 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma Hit paper breakdown → | 2018 | 1296 |
| 14 | Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing Hit paper breakdown → | 2018 | 1155 |
| 15 | Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 1010 |
| 16 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma Hit paper breakdown → | 2018 | 946 |
| 17 | Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy Hit paper breakdown → | 2016 | 938 |
| 18 | TOX is a critical regulator of tumour-specific T cell differentiation Hit paper breakdown → | 2019 | 853 |
| 19 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 851 |
| 20 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 842 |
About Matthew David Hellmann
Matthew David Hellmann is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 244 papers that have together received 77.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (151 papers), Lung Cancer Treatments and Mutations (65 papers), Cancer Genomics and Diagnostics (34 papers), CAR-T cell therapy research (29 papers), Lung Cancer Research Studies (29 papers), Immunotherapy and Immune Responses (24 papers), Immune Cell Function and Interaction (16 papers) and Lung Cancer Diagnosis and Treatment (14 papers). The work is most often cited by research in Oncology (47.2k citations), Immunology (17.5k citations), Cancer Research (10.9k citations), Pulmonary and Respiratory Medicine (20.8k citations) and Pathology and Forensic Medicine (4.0k citations). Matthew David Hellmann has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Michael Andrew Postow, Robert Sidlow, Adam Jacob Schoenfeld, Jedd D. Wolchok, Mark G. Kris, Jamie E. Chaft, Hira A. Rizvi, Naiyer A. Rizvi, Scott Joseph Antonia and Gregory J. Riely. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.